The synthesis and quality control of 18F-FDG and 18F-FES were performed as reported in our previous study (15 (link)).
18F-FDG PET/CT imaging was done according to standard clinical procedures. All patients fasted for at least 6 h and had serum glucose levels less than 10 mmol/L before the intravenous injection of 18F-FDG (3.7–7.4 MBq/kg). The patients were kept lying comfortably in a quiet, dimly lit room before and after the tracer injection. About 1 h after tracer injection, the patients were administered 1 L of plain water orally and then scanned in the PET/CT (Siemens Biograph 16HR PET/CT or mCT Flow PET/CT scanner). About 222 MBq of 18F-FES was injected intravenously over 1–2 min. The scanning was initiated 1 h after administration of the tracer on the same PET/CT scanner as the 18F-FDG. The detail of PET/CT acquisition parameters were described as reported in prior studies (16 (link)).
18F-FDG PET/CT imaging was done according to standard clinical procedures. All patients fasted for at least 6 h and had serum glucose levels less than 10 mmol/L before the intravenous injection of 18F-FDG (3.7–7.4 MBq/kg). The patients were kept lying comfortably in a quiet, dimly lit room before and after the tracer injection. About 1 h after tracer injection, the patients were administered 1 L of plain water orally and then scanned in the PET/CT (Siemens Biograph 16HR PET/CT or mCT Flow PET/CT scanner). About 222 MBq of 18F-FES was injected intravenously over 1–2 min. The scanning was initiated 1 h after administration of the tracer on the same PET/CT scanner as the 18F-FDG. The detail of PET/CT acquisition parameters were described as reported in prior studies (16 (link)).
Free full text: Click here
